Abbott strikes deals with heart valve replacement companies
(Reuters) – Abbott Laboratories on Thursday said it would buy a small private company and has invested in another, with an option to buy, as it places bets on the future growth potential of minimally invasive systems to replace diseased heart valves. Abbott said it has agreed to acquire the equity in Minnesota-based Tendyne Holdings Inc that it does not already own for $250 million plus future payments tied to